Anixa Biosciences Inc. (ANIX)
2.56
-0.04 (-1.54%)
At close: Apr 04, 2025, 3:47 PM
-1.54% (1D)
| Bid | 2.51 |
| Market Cap | 82.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | -6.56 |
| Forward PE | -7.78 |
| Analyst | Buy |
| Ask | 2.59 |
| Volume | 60,239 |
| Avg. Volume (20D) | 104,000 |
| Open | 2.54 |
| Previous Close | 2.60 |
| Day's Range | 2.44 - 2.70 |
| 52-Week Range | 2.07 - 4.20 |
| Beta | 0.52 |
About ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the t...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 7, 1983
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ANIX
Website https://www.anixa.com
Analyst Forecast
According to 4 analyst ratings, the average rating for ANIX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 290.63% from the latest price.
Stock Forecasts2 months ago
+6.05%
Anixa Biosciences shares are trading higher. D Bor...
Unlock content with
Pro Subscription
2 months ago
+16.6%
Anixa Biosciences shares are trading higher after the company highlighted key business milestones for 2024 and outlined goals for the next year.
